Ogawan, Victoria S.

HRN: 18-43-08  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/02/2023
CO-AMOXICLAV 625MG (TAB)
08/02/2023
08/10/2023
PO
625mg
BID
7 Days
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: No  Wrong Choice  Wrong Choice

Overall appropriateness: No  Wrong Choice

Intervention



Type of Intervention done:

                    

           


Acceptance: